Literature DB >> 17394096

The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes.

Andrew Lowey1, Sara Moore, Catherine Norris, David Wright, Jonathan Silcock, Peter Hammond.   

Abstract

AIM: People with type 2 diabetes mellitus have an increased risk of cardiovascular and cerebrovascular disease compared with the general population. Following attempts to change lifestyle, pharmacological treatment is necessary to modify this risk. However, the use of medicines may be sub-optimal because of infrequent or inadequate medication review.
SETTING: Harrogate District Hospital, a medium-sized district general hospital in a rural area of North Yorkshire, England.
METHOD: A pharmacist-led hospital clinic was established to manage diabetic patients suffering from resistant hypertension with or without hyperlipidaemia. Patients with two consecutive elevated blood pressure (BP) readings (>140/80 mmHg) were recruited via referral from out-patient clinics and diabetic nurse specialists. A range of clinical indicators were assessed on referral. The pharmacist prepared individualised patient information and a patient-held record card. An evidence-based algorithm was used to make adjustments (every 4 weeks) to anti-hypertensive medication. If necessary treatment of hyperlipidaemia was also optimised. Published data was used to predict the 10-year risk of coronary heart disease and cerebrovascular accident for each patient before and after intensive medicines management. Patients were discharged from the clinic after two consecutive target BP measurements.
RESULTS: It is estimated that these risks were reduced by 11.9 and 9.6%, respectively, at a cost per event avoided of pound 34,708 and pound 63,320.
CONCLUSION: Intensive pharmacist-led clinics are potentially a cost-effective way to improve the cardiovascular health of patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17394096     DOI: 10.1007/s11096-007-9101-7

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  12 in total

1.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

2.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

Authors:  A I Adler; I M Stratton; H A Neil; J S Yudkin; D R Matthews; C A Cull; A D Wright; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

3.  The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

Authors:  R J Stevens; V Kothari; A I Adler; I M Stratton
Journal:  Clin Sci (Lond)       Date:  2001-12       Impact factor: 6.124

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

Review 5.  Guidelines for management of hypertension: report of the third working party of the British Hypertension Society.

Authors:  L Ramsay; B Williams; G Johnston; G MacGregor; L Poston; J Potter; N Poulter; G Russell
Journal:  J Hum Hypertens       Date:  1999-09       Impact factor: 3.012

6.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

7.  Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Authors:  K Pyŏrälä; T R Pedersen; J Kjekshus; O Faergeman; A G Olsson; G Thorgeirsson
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

8.  A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.

Authors:  Anders G Olsson; Mats Eriksson; Owe Johnson; Thomas Kjellström; Jan Lanke; Mogens Lytken Larsen; Terje Pedersen; Matti J Tikkanen; Olov Wiklund
Journal:  Clin Ther       Date:  2003-01       Impact factor: 3.393

Review 9.  Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials.

Authors:  H Yki-Järvinen
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  7 in total

Review 1.  Economics of Team-based Care in Controlling Blood Pressure: A Community Guide Systematic Review.

Authors:  Verughese Jacob; Sajal K Chattopadhyay; Anilkrishna B Thota; Krista K Proia; Gibril Njie; David P Hopkins; Ramona K C Finnie; Nicolaas P Pronk; Thomas E Kottke
Journal:  Am J Prev Med       Date:  2015-11       Impact factor: 5.043

Review 2.  A review of the methodological challenges in assessing the cost effectiveness of pharmacist interventions.

Authors:  Rachel A Elliott; Koen Putman; James Davies; Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981

Review 3.  Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care.

Authors:  Greg Weeks; Johnson George; Katie Maclure; Derek Stewart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-22

4.  Evaluation of educational needs in patients with diabetes mellitus in respect of medication use in Austria.

Authors:  Rosa Lemmens-Gruber; Christine Hahnenkamp; Ulrike Gössmann; Jürgen Harreiter; Majid-Reza Kamyar; Barbara Julienne Johnson; Steve Hudson; Alexandra Kautzky-Willer
Journal:  Int J Clin Pharm       Date:  2012-04-24

5.  Collaborative Cardiovascular Risk Reduction in Primary Care II (CCARP II): Implementation of a systematic case-finding process for patients with uncontrolled risk factors.

Authors:  Erin M Yakiwchuk; Derek Jorgenson; Kerry Mansell; Tessa Laubscher; Marlys Lebras; David F Blackburn
Journal:  Can Pharm J (Ott)       Date:  2013-09

6.  Economic evaluation of home blood pressure monitoring with or without telephonic behavioral self-management in patients with hypertension.

Authors:  Shelby D Reed; Yanhong Li; Eugene Z Oddone; Alice M Neary; Melinda M Orr; Janet M Grubber; Felicia L Graham; Maren K Olsen; Laura P Svetkey; Rowena J Dolor; Benjamin J Powers; Martha B Adams; Hayden B Bosworth
Journal:  Am J Hypertens       Date:  2009-11-19       Impact factor: 2.689

7.  Supervised pharmacy student-led medication review in primary care for patients with type 2 diabetes: a randomised controlled pilot study.

Authors:  R P Adams; G Barton; D Bhattacharya; P F Grassby; R Holland; A Howe; N Norris; L Shepstone; D J Wright
Journal:  BMJ Open       Date:  2015-11-04       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.